Inotiv Competitors

Arcutis Biotherapeutics (NASDAQ:ARQT) and Inotiv (NASDAQ:NOTV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Arcutis Biotherapeutics and Inotiv, as provided by MarketBeat.com.

Arcutis Biotherapeutics currently has a consensus target price of $54.6667, suggesting a potential upside of 67.95%. Given Arcutis Biotherapeutics' higher possible upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Inotiv.

Profitability

This table compares Arcutis Biotherapeutics and Inotiv's net margins, return on equity and return on assets.

Institutional & Insider Ownership

79.6% of Arcutis Biotherapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Arcutis Biotherapeutics and Inotiv's revenue, earnings per share and valuation.

Summary

Arcutis Biotherapeutics beats Inotiv on 3 of the 5 factors compared between the two stocks.

Atea Pharmaceuticals (NASDAQ:AVIR) and Inotiv (NASDAQ:NOTV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for Atea Pharmaceuticals and Inotiv, as provided by MarketBeat.

Atea Pharmaceuticals presently has a consensus target price of $69.3333, suggesting a potential upside of 253.20%. Given Atea Pharmaceuticals' higher possible upside, equities analysts clearly believe Atea Pharmaceuticals is more favorable than Inotiv.

Earnings and Valuation

This table compares Atea Pharmaceuticals and Inotiv's top-line revenue, earnings per share and valuation.

Profitability

This table compares Atea Pharmaceuticals and Inotiv's net margins, return on equity and return on assets.

Summary

Atea Pharmaceuticals beats Inotiv on 2 of the 2 factors compared between the two stocks.

Inotiv (NASDAQ:NOTV) and Establishment Labs (NASDAQ:ESTA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

54.8% of Establishment Labs shares are owned by institutional investors. 2.6% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Inotiv and Establishment Labs, as reported by MarketBeat.com.

Establishment Labs has a consensus price target of $46.00, suggesting a potential downside of 32.55%. Given Establishment Labs' higher probable upside, analysts plainly believe Establishment Labs is more favorable than Inotiv.

Earnings & Valuation

This table compares Inotiv and Establishment Labs' top-line revenue, earnings per share and valuation.

Inotiv has higher earnings, but lower revenue than Establishment Labs.

Profitability

This table compares Inotiv and Establishment Labs' net margins, return on equity and return on assets.

Summary

Establishment Labs beats Inotiv on 5 of the 8 factors compared between the two stocks.

Inotiv (NASDAQ:NOTV) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Insider and Institutional Ownership

99.0% of Heron Therapeutics shares are owned by institutional investors. 12.9% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Inotiv and Heron Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for Inotiv and Heron Therapeutics, as reported by MarketBeat.com.

Heron Therapeutics has a consensus target price of $26.00, indicating a potential upside of 48.06%. Given Heron Therapeutics' higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than Inotiv.

Earnings & Valuation

This table compares Inotiv and Heron Therapeutics' gross revenue, earnings per share and valuation.

Inotiv has higher earnings, but lower revenue than Heron Therapeutics.

Summary

Heron Therapeutics beats Inotiv on 5 of the 8 factors compared between the two stocks.

Inotiv (NASDAQ:NOTV) and Amneal Pharmaceuticals (NYSE:AMRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Insider and Institutional Ownership

33.5% of Amneal Pharmaceuticals shares are owned by institutional investors. 26.3% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Inotiv and Amneal Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for Inotiv and Amneal Pharmaceuticals, as reported by MarketBeat.com.

Amneal Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 31.83%. Given Amneal Pharmaceuticals' higher possible upside, analysts plainly believe Amneal Pharmaceuticals is more favorable than Inotiv.

Earnings & Valuation

This table compares Inotiv and Amneal Pharmaceuticals' gross revenue, earnings per share and valuation.

Inotiv has higher earnings, but lower revenue than Amneal Pharmaceuticals.

Summary

Amneal Pharmaceuticals beats Inotiv on 8 of the 8 factors compared between the two stocks.

Inotiv (NASDAQ:NOTV) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.

Institutional and Insider Ownership

55.8% of Replimune Group shares are owned by institutional investors. 50.9% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Inotiv and Replimune Group's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Inotiv and Replimune Group, as reported by MarketBeat.

Replimune Group has a consensus target price of $56.00, indicating a potential upside of 64.75%. Given Replimune Group's higher possible upside, analysts plainly believe Replimune Group is more favorable than Inotiv.

Valuation & Earnings

This table compares Inotiv and Replimune Group's gross revenue, earnings per share and valuation.

Summary

Replimune Group beats Inotiv on 4 of the 6 factors compared between the two stocks.